Protalix BioTherapeutics (PLX) Liabilities and Shareholders Equity (2010 - 2026)

Protalix BioTherapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $102.3 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 38.49% year-over-year to $102.3 million; the TTM figure through Mar 2026 stood at $345.4 million (up 14.99% YoY), while the FY2025 annual figure was $82.3 million, up 12.16% from the prior year.
• Liabilities and Shareholders Equity was $102.3 million for Q1 2026 at Protalix BioTherapeutics, up from $82.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $102.3 million in Q1 2026 to a low of $55.8 million in Q4 2022.
• Historically, Liabilities and Shareholders Equity has averaged $76.7 million across 5 years, with a median of $78.5 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity sank 43.96% in 2022, then soared 54.42% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $55.8 million in 2022, then soared by 51.35% to $84.4 million in 2023, then fell by 13.05% to $73.4 million in 2024, then increased by 12.16% to $82.3 million in 2025, then grew by 24.28% to $102.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $102.3 million (Q1 2026), $82.3 million (Q4 2025), and $82.3 million (Q3 2025), per Business Quant data.